Common Contracts
4 similar null contracts by Crinetics Pharmaceuticals, Inc., Moove Lubricants Holdings, StandardAero, Inc., Upstream Bio, Inc.
CRINETICS PHARMACEUTICALS, INC. 10,000,000 Shares of Common Stock, par value $0.001 per share Underwriting AgreementCrinetics Pharmaceuticals, Inc. • October 9th, 2024 • Pharmaceutical preparations • New York
Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 10,000,000 shares of common stock, par value $0.001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to 1,500,000 additional shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
Upstream Bio, Inc. [•] Shares of Common Stock, par value $0.001 per share Underwriting AgreementUpstream Bio, Inc. • October 7th, 2024 • Pharmaceutical preparations • New York
MOOVE LUBRICANTS HOLDINGS [25,000,000] Common Shares, par value US$0.000333333333333 per share Underwriting AgreementMoove Lubricants Holdings • October 1st, 2024 • Miscellaneous products of petroleum & coal • New York
Moove Lubricants Holdings, a Cayman Islands exempted company with limited liability (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [6,250,000] common shares, par value US$0.000333333333333 per share, of the Company, the shareholder of the Company named in Section 1 of Schedule 2 hereto (“Cosan”) and the shareholder of the Company named in Section 2 of Schedule 2 hereto (the “CVC Fund VII” and, together with Cosan, the “Selling Shareholders”) propose to sell to the several Underwriters an aggregate of [18,750,000] common shares of the Company (collectively, the “Underwritten Shares”). In addition, the Selling Shareholders propose to sell, at the option of the Underwriters, up to an additional [3,750,000] common shares of the Company (collectively, the “Option Shares”). The Underwritten Shares and the Option Shares are herein refer
STANDARDAERO, INC. 60,000,000 Shares of Common Stock Underwriting AgreementStandardAero, Inc. • September 27th, 2024 • Aircraft engines & engine parts • New York
StandardAero, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 53,250,000 shares of common stock, par value $0.01 per share, of the Company (the “Common Stock”), and certain stockholders of the Company named in Schedule 2 hereto (the “Selling Stockholders”) propose to sell to the several Underwriters an aggregate of 6,750,000 shares of Common Stock of the Company (collectively, the “Underwritten Shares”). In addition, the Selling Stockholders propose to sell, at the option of the Underwriters, up to an additional 9,000,000 shares of Common Stock of the Company (collectively, the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock to be outstanding after giving effect to the sale of the Shares are referred to herein as the “St
